Biotech · Private company
ADIR, a Servier Group company
Track this companyFree. Adds ADIR, a Servier Group company to your Dealase workspace and tells you when its record changes.
Clinical trials81 recruiting or active
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Clinical trials8
- Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal CancerPHASE3 · TERMINATED · started Apr 21, 2022ClinicalTrials.gov NCT05223673 · fetched Nov 12, 2026
- S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal CancersPHASE1 · COMPLETED · started Oct 15, 2021ClinicalTrials.gov NCT05162755 · fetched Nov 12, 2026
- Efficacy and Safety of S95011 in Primary Sjögren's Syndrome PatientsPHASE2 · COMPLETED · started Aug 3, 2021ClinicalTrials.gov NCT04605978 · fetched Nov 12, 2026
- A Study to Evaluate the Long-term Safety of Patients With Advanced Lymphoid Leukemia Who Have Been Previously Administered With UCART19PHASE1 · ACTIVE_NOT_RECRUITING · started Mar 10, 2021ClinicalTrials.gov NCT02735083 · fetched Nov 12, 2026
- Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid LeukaemiaPHASE1_PHASE2 · COMPLETED · started Feb 17, 2021ClinicalTrials.gov NCT04629443 · fetched Nov 12, 2026
- Phase I Dose Escalation Study of Intravenously Administered S64315 in Combination With Orally Administered Venetoclax in Patients With Acute Myeloid Leukaemia.PHASE1 · COMPLETED · started Nov 28, 2018ClinicalTrials.gov NCT03672695 · fetched Nov 12, 2026
- Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.PHASE3 · TERMINATED · started Oct 4, 2018ClinicalTrials.gov NCT03715153 · fetched Nov 12, 2026
- Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic SyndromePHASE1 · COMPLETED · started Mar 15, 2017ClinicalTrials.gov NCT02979366 · fetched Nov 12, 2026